Persistent pulmonary hypertension of the newborn. Persistent fetal circulation
Conditions
Interventions
Intervention 1: Intervention group: Bosentan tablets (manufactured by Faran Shimi, Iran) with a concentration of 1 mg/kg and Sildenafil (Alborz Darou) with a concentration of 0.4 mg /kg every 12 hours
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Days to 1 Months
Inclusion criteria
Inclusion criteria: Parents' satisfaction to participate in the study Newborns with respiratory symptoms, decreased arterial oxygen saturation, and cyanosis Pulmonary artery pressure greater than or equal to 25 mmHg and severity of tricuspid valve failure greater than or equal to 30 mmHg with or without right-to-left shunt
Exclusion criteria
Exclusion criteria: Cyanotic heart diseases Other diseases cyanosis Increased pulmonary artery pressure due to pneumonia or meconium aspiration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Persistent Pulmonary Hypertension of the Newborn. Timepoint: The beginning of the study, 6 and 12 days after the intervention. Method of measurement: Echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSama dabbagh
Iran University of Medical Sciences
Outcome results
None listed